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Hepatitis G virus infection in hemodialysis patients. The increased risk
of hemodialysis patients for infections sustained by hepatitis viruses is
likely to extend to a newly discovered parenterally transmitted virus,
HGBV-C/HGV, able to cause acute and chronic hepatitis. The aim of this
study was to assess the prevalence and clinical relevance of this infection
in Italian hemodialysis patients. Nineteen of 100 patients (19%) on
maintenance hemodialysis were viremic for HGBV-C/HGV, and all of
them were infected with a HGV-like genotype. Eight of these patients
were coinfected by hepatitis B or hepatitis C viruses. A clinical picture of
chronic hepatitis was not appreciable in patients with isolated HGV
infection and the presence of HGV did not appear to modify the clinical
course of hepatitis B and hepatitis C infections.
Patients on maintenance hemodialysis (HD) are at increased
risk of infection with parenterally transmitted viral agents. Non-A,
non-B hepatitis was recognized as a relevant problem for HD
patients in the 1970s [1] and in recent years, after the identifica-
tion of hepatitis C virus (HCV) [2] and the introduction of
diagnostic tests able to detect antibodies against HCV [3], veiy
high prevalence rates of HCV infection, not uncommonly exceed-
ing 50%, were described in several HD units [reviewed in 4].
Although HCV infection can be caused in many cases by blood
transfusions [5, 61, the possibility of a nosocomial infection has
become increasingly more evident and in few instances a detailed
virological analysis was able to demonstrate patient to patient
transmission [7—9].
The increased risk of HD patients for HCV infection is likely to
extend to a recently identified group of viral hepatotropic agents
belonging to the Flaviviridae and distantly related to HCV, which
can cause acute and chronic hepatitis. It includes hepatitis GB
virus A (I IGBV-A) and hepatitis GB virus B (HGBV-B) [10], the
closely related hepatitis GB virus C (IIGBV-C) [11], and hepatitis
G virus [12]. On the basis of sequence homology it is likely that
HGBV-C and HGV represent different genotypes of the same
virus. The virological features of these new agents, deduced from
the sequence of their genome and preliminary clinical observa-
tions, should be similar to those of HCV. In particular they appear
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to share with HCV modes of transmission and the ability to cause
a chronic infection. Among the HD population, an increased
frequency of infection with the HGBV-C genotype compared to
the general population has been reported by Masuko et al [13],
who also described the apparently mild clinical course of the
infection in HD patients.
The aim of this study was to assess the prevalence and clinical
relevance of the infection in a group of Italian HD patients, taking
into consideration both HGBV-C and HGV genotypes and their
relationship with risk factors such as blood transfusions and time
on HD, and with present or past infection with HBV and HCV.
The risk factors and clinical pictures of patients with HGBV-C/
HGV infection were compared with those of patients infected
with HBV and HCV in order to acquire information on the origin
and natural history of this infection in the HD environment.
Methods
Patients
This study was performed on all the 100 patients on chronic HD
treatment in the two separated dialysis units of our hospital after
informed consent was obtained from each patient. Hospital
records of each patient were reviewed for medical history, hepa-
titis B virus (HBV) and HCV serology, liver biochemistry and
blood transfusions, Increased alanine transferase (ALT) levels
were defined by values greater than twice the upper value of
normal range. Isolation measures had been introduced for HBsAg
positive patients since 1970s, and for HCV positive patients since
1992 in unit B and since 1995 in unit A. All HD patients studied
were Italians from different regions of Italy, except for one patient
of unit A who was from Egypt and one patient in unit B from
Rumania, all had been living in the area of Milano for several
years.
Methods
All serum samples were collected in November 1995, aliquotcd
and stored at —70CC. HBV markers HBsAg, HBsAb and HBcAb
and l-ICV antibodies were determined in all patients by enzyme-
linked immunoassays (Abbott Laboratories, North Chicago, IL,
USA for HBV markers and Ortho Diagnostic Systems, Raritan,
NJ, USA for anti-HCV). HCV and HGV RNAs were extracted
from 100 1id of serum by spin-chromatography (OIAamp HCV kit;
Qiagen GmhH, Hilden, Germany). Qualitative detection of HCV
RNA was performed by a single-tube reverse-transcription (RT)
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Age years 58.1 15 59.7 11.6 56.8 17.0
SexM—F 52—48 9—10 43—38
Time on HD months 117 94 113 98 117 99
History of transfusion 55 (55%) 12 (63%) 43 (53%)
Number of transfusions 3 4 3
median/(range) (1—23) (1—Il) (1—23)
History of high ALT 29 (29%) 7 (37%) 22 (27%)
HBsAg+ 12(12%) 2(10%) 10(12%)
HBcAb+ 45 (45%) 8 (42%) 37 (46%)
HCV-RNA+ 24(24%) 4(21%) 20(25%)
Anti-HCV+ 45 (45%) 8 (42%) 37 (46%)
None of the observed differences was statistically significant.
heminested polymerase chain reaction (PCR) procedure as pre-
viously described [14] with primers from the 5'-untranslated
region (5'-UTR) of the viral genome. HCV genotyping was
performed by endonuclease cleavage of the amplified 5' non-
coding region according to [15] with minor modifications and
HCV genotypes were classified according to the nomenclature
proposed by Simmonds [161. Reverse transcription and amplifi-
cation of HGBV-C/HGV were performed by the same single-tube
procedure used for HCV, using primers from the 5'-UTR of
HGBV-C/HGV. Primers(R-G,5 '-TGGACCGTACGTGGGCGT-
CGTfTGCCCAGG-3', RT and common reverse primer in PCR;
FEX-G, 5 '-CTCGGCGACCGGCCAAAAGGTGGTGGATGG-
3', forward external primer in heminested PCR; FIN-G, 5'-TGG-
TAGCCACTATAGG-3', forward internal primer) were deduced
from the alignment of published sequences of HGBV-C and HGV
as well as on personal sequence data, and would amplify all
published HGBV-C and HGV sequences. Samples testing posi-
tive and a subset of negative ones were re-tested with a commer-
cial assay strictly specific for HGV (HGV Primer and Capture
Probe Set; Boehringer Mannheim GmbH, Mannheim, Germany).
Nucleotide sequence of cloned PCR products from two patients
was determined using a cycle-sequencing protocol (DNA Termi-
nator Cycle Sequencing Kit; Perkin-Elmer, Foster City, CA,
USA) incorporating fluorescent dye-terminators and analysis on
an automatic sequencer (373A; Applied Biosystems, Foster City,
CA, USA). In a subset of samples 5'UTR amplified sequences
were further characterized by restriction analysis with the en-
zymes AvaIl, Hinfl, HaeIIl and MnlI and patterns compared with
those expected for the prototype sequences of HGBV-C and
HGV.
Statistical analyses were performed by Fisher's exact test, the
unpaired f-test and ANOVA with Bonferroni correction.
Results
Table I reports the most relevant clinical and serological data
of the patients studied. Nineteen patients (19%) tested positive
for HGBV-CIHGV RNA, Among them 6 were on chronic
treatment in unit A and 13 in unit B. All the six patients from unit
A, consisting of four rooms, had been treated for 8 to 260 months
in the same room, while the distribution of the 13 positive patients
in the three rooms of unit B was scattered.
Further testing of positive samples with a HGV-specific assay
confirmed the presence of a HGV-like sequence in 15 of 19, while
ten samples negative at the initial assay were confirmed as
negative. Sequence analysis of three clones from one of these
products (HGVptA3) allowed to establish a consensus sequence
showing 98.9% identity with the two HGV isolates, HGV-U44402
and HGV-U45966 (Fig. 1) characterized by Linnen et al [12].
Four of the 19 patients positive at the HGBV-C/HGV assay tested
negative with the HGV-specific assay. When subjected to multiple
restriction analysis these four PCR products did show the ex-
pected pattern for a HGV 5'UTR sequence. Sequence analysis of
three clones obtained from one of these products (HGVptB1)
revealed a HGV-like sequence with 97.7% identity with HGV-
U44402 and HGV-U45966 (Fig. 1).
The presence of HGV was not significantly related to age and
sex of patients, time on HD, history of transfusion or increased
transaminases, nor to the presence of HBV and HCV markers
(Table 1). In particular, the mean time on HD was almost
identical in the two groups and 12 of 19 patients (63%) with HGV
had received blood transfusion in the past, a proportion similar to
that found in HGV-negative patients. No relationship was ob-
served between HGV positivity and clinical evidence of liver
inflammation, evaluated by past episodes of hypertransaminas-
emia and mean levels of transaminases of the last six months. The
virological and serological profile for HBV and HCV showed that
HGV-positive and HGV-negative HD patients had a similar
frequency of present or past infection with these two viruses.
Twelve patients (12%) (6 from unit A and 6 from unit B) were
chronic carriers of HBsAg and serological evidence of past HBV
infection, witnessed by HBcAb positivity, was present in 45
patients (45%). Twenty-four patients (24%) (5 from unit A and 19
from unit B) were viremic for HCV. The frequency of HCV
viremia was significantly different in the two units (P = 0.005,
Fisher's exact test). Antibodies against HCV were found in 45
patients (45%). Fifty-three percent of patients with HCV antibod-
ies were viremic while no patients had a positive PCR for HCV in
the absence of detectable anti-HCV antibodies. HCV genotypes
characterized in vircmic patients were HCV1a in one case,
HCVIb in 12, HCV2a in 3 and HCV4 in 8. HCV4 was found only
among patients from unit B.
In Table 2 clinical data of patients with isolated HBV, HCV and
HGV viremia are compared. Patients with isolated HBV or HCV
infection had been on HD for a significantly longer time com-
pared with patients with isolated HGV infection and non-viremic
patients (P < 0.0001). A history of increased ALT was more
frequently present in patients with HBV or HCV viremia and
mean ALT levels of the last six moths were significantly higher in
FIBV and I-ICV infections. ALT levels of HGV viremic patients
were similar to those of non-viremic controls. Only two of 13
patients with isolated HGV viremia had a history of hyper
transaminasemia; of these, one had a serology indicating a
resolved HBV infection while the other was negative for HBV and
HCV markers, This patient, treated by peritoneal dialysis between
1989 and 1992 and on HD since 1992, had a single episode of
increased ALT in 1993, one year after receiving the last of five
blood transfusions. Among the non-viremic patients 7 had epi-
sodes of hypertransaminasemia in the past; of these, 6 were
positive for antibodies against HBV and/or HCV.
Eight patients were found to be coinfected by different viruses:
2 with HBV and HCV, 2 with HBV and HGV, 4 with HCV arid
HGV. Clinical features of patients with HCV/HGV and HBV/
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Fig. 1. Alignment of the sequence of 177 base pairs from the 5' UTR of HGV cloned from two HG V-positive hemodialysis patients (ptA3 and ptBl) with the
sequence of HGV (GenBank accession number U44402 and U45966) and HGBV-C (GenBank accession number U36380).
Table 2. Clinical data and risk factors of patients viremic for HBV,
HCV and HGV, and of non-viremic patients
HBV+ HBV- HBV HBV-
HCV- HCV+ HCV- HCV-
HGV- HGV- HGV+ HGV-
N=8 N=18 N=13 N=53 P
Age years 53.1 10.7 56.2 2.9 60.1 3.5 58.7 2.4 NS
Sex M—F 5—3 9—9 7—6 23—30 NS
Time on dialysis 193 109 190 91 77 74 87 70 0.0001"
months
History of 6 (75%) 10 (56%) 7(54%) 21(40%) NS
transfusions
Number of 3.5 3 5 3 NS
transfusions" (1—10) (1—20) (1—10) (1—23)
median/(range)
History of 3 (38%) 7 (39%) 2 (15%) 7 (13%) NS
ALT> 2N
Mean ALT last 33 22 27 15 17 8 14 6 0.0001'
6 months
a Columns I and 2 vs. columns 3 and 4
In transfused patients
"Column 1 vs. columns 3 and 4; column 2 vs. column 4
HGV coinfections, reported in Table 3, were similar to those
observed in patients with isolated HCV or HBV infection.
Discussion
Within the novel group of Flaviviridae including HGBV-A, -B
and -C, and HGV, only for HGBV-C and HGV convincing data
are available that they are human pathogens, while the human
origin of HGBV-A and-B has been questioned [171. HGBV-Cwas
found in blood donors [13], in acute hepatitis [11], in fulminant
hepatitis [181, in intravenous drug abusers [191 and in HD patients
[13]. The presence of HGV has been reported in acute and
chronic liver disease, and, among patients with a high parenteral
exposure risk, in hemophiliacs, polytransfused patients with
chronic anemia and intravenous drug abusers [121.
All the investigations on HGBV-C and HGV so far reported
are based on PCR methodologies specific for one of the two
viruses. Since HGBV-C and HGV could represent different
genotypes of the same virus, we investigated the presence of
HGBV-C/HGV in 100 HD patients using a PCR assay able to
recognize both these viral genotypes, based on the amplification
of conserved sequences in the 5'UTR of the viral genome.
The prevalence data demonstrate that the high risk of HD
patients for HCV infection extends to the recently identified
HGBV-C/HGV. The 19% prevalence of HGV infection among
our patients was significantly higher than that recently reported in
Japanese patients by Masuko et al [13], who found a prevalence of
3.1% HGBV-C infection in 519 HD patients. HCV-RNA was
detected in 20.6% Japanese HD patients [131, a proportion seven
times greater than that of HGBV-C in the same group, while in
the HD patients examined by us the prevalence of HGBV-C/
HGV was only slightly lower than the prevalence of HCV (19%
vs. 24%).
Several factors could account for the higher prevalence of
HGBV-C/HGV we found compared with that reported by Ma-
suko et al [13], not the least which is a genuinely lower risk for
Japanese HD patients to be infected by this viral agent. However,
as the same authors point out, the PCR primers they used were
complementary to a variable HGBV-C sequence, and mismatches
within the primer sequences could prevent the amplification of
some HGBV-CIHGV genotypes or decrease the sensitivity of
their assay. It is therefore possible that the prevalence they report
undervalues the actual epidemiological relevance of the infection
among HD patients.
It has been postulated that HGBV-C and HGV could represent
different genotypes of the same virus. At present, however, a
classification of HGBV-C/HGV genotypes is not available and
little is known of their geographical distribution. HGBV-C was
initially isolated from West African and North American samples
[11], and subsequently in Japan [13, 18]. HGV was detected in
serum samples from patients in the U.S., Australia, South Amer-
ica and Europe [12]. Extensive analysis of our HGBV-C/HGV
positive samples by a combination of HGV-specific PCR and
oligonucleotide hybridization, restriction analysis and sequencing
indicates that all our HGBV-C/HGV positive patients are in fact
infected with a HGV-like virus whose 5'UTR sequence is ex-
tremely similar to the two characterized by Linnen et al [121.
Therefore, even if an analysis of other regions of the viral genome
will be needed to confirm this issue, HGV appears to be the
predominant strain in our population.
While our assay was expressly designed to identify both
HGBV-C and HGV, assays designed for the non-structural region
of HGBV-C could also unpredictably recognize, possibly with a
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Age years/sex M—F 51/F 69/F 46/M 73/F Sl/M 62/M
Time on dialysis months 228 48 265 84 336 152
Number of transfusions 3 10 3 0 2 10
History of ALT > 2N yes yes yes no yes yes
Mean ALT last 6 months 23 117 24 16 23 7
commercial diagnostic assay for HGV which we used for supple-
mental testing could not recognize the 5'UTR of HGBV-C
because of a severe primer mismatch. Therefore, at this stage of
the knowledge of this novel group of viruses, it is necessary to
account for the influence that different methodological ap-
proaches may have on results used to establish epidemiology.
Clinical and serological features of patients sorted according to
their HGV status did not differ significantly. Since a relevant
proportion (3 1.6%) of HGV positive patients were coinfected by
HBV or HCV, which would interfere with the definition of the
clinical picture of HGV infection, in order to evaluate the clinical
features associated to the virological status we examined three
groups of patients with isolated HBV, HCV and HGV viremia,
compared with a group of non-viremic patients. Patients with
HBV or HCV infection had been on HD for a significantly longer
period compared with HGV-positive and non-viremic patients.
However, the proportion of transfused patients and the mean
number of transfused blood units was not different in the four
groups, suggesting the relevance of other modes of inapparent
parenteral transmission in the HD setting. The shorter time on
HD of patiens with isolated HGV viremia could be conditioned by
the high proportion of HCV/HGV coinfections with longer time
on HD. When only the HGV status is considered, the duration of
HD treatment in HGV-negative and positive patients is identical.
In the absence of an assay for HGV antibodies and of serial
determinations to establish the length of infection, a larger
number of patients will be needed to establish the actual HD-
related risk to acquire HGV infection. Only two patients among
the 13 with isolated HGV viremia had a history of hypertransami-
nasemia, one of them in the absence of HBV and HCV serological
markers. At the time of a single transient increase of ALT this
patient had not been transfused for twelve months, making it
unlikely, in this case, that the acquisition of HGV was through
blood transfusion.
In conclusion, a clinical picture of chronic hepatitis sustained by
HGV infection was not appreciable in these HD patients. The
features of patients with isolated HGV viremia were not distin-
guishable from those of non-viremic patients, and in coinfections
of HBV and HCV with HGV the presence of HGV did not
appear to worsen the clinical course of HBV and HCV chronic
infections.
The different prevalence and the distribution of HCV and HGV
infections in the two HD units of our department extends the
concern about nosocomial spread of HCV to the newly discovered
HGV. In a previous study we demonstrated that the high preva-
lence of HCV in unit B of our department was associated with the
presence of a rare HCV genotype, and could be plausibly ex-
plained by nosocomial transmission [8]. Also, HGV was more
frequent in our unit B (12.5% in unit A vs. 25% in unit B) and the
6 HGV-positive patients from unit A had all been treated for a
prolonged period in the same room, sharing personnel care and
monitors. These findings could indirectly suggest a nosocomial
spread of HGV in the HD setting. More detailed analysis of HGV
isolates as well as epidemiological studies will be needed to
establish this issue.
The high prevalence of a newly discovered parenterally trans-
mitted virus in hemodialysis patients also raises the issue of
infection control measures. While for patients or monitors segre-
gation is almost universally applied to control HBV infection, and
it has been suggested and sometimes implemented for I-ICy, the
recognition of a new frequent infection makes it increasingly
unfeasible, in terms of organization and material resources, to use
this approach. At least eight groups of patients, sorted by their
virological status, are theoretically to be dealt with: non-viremic,
HBV, HCV and HGV infections, HBV/HCV, HBV/HGV, HCV/
HGV and HBV/HCV!HGV coinfections. This is without taking
into consideration the multiple genotypes of these viruses and the
lack of protective immunity for HCV and possibly HGV, which
expose this group of patients to the risk of re-infections and
super-infections. Only by improving the standards and the rigor-
ous application of infection control measures can healthcare
workers concretely lessen the high risk of HD patients to become
infected by one of the major hepatitis viruses.
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